Abstract Search

ea0099ep320 | Pituitary and Neuroendocrinology | ECE2024

An open-label long-term Phase 3 study of CAM2029 in patients with acromegaly (ACROINNOVA 2): interim analysis of the subgroup of patients ‘new to CAM2029’ with controlled or uncontrolled acromegaly on standard-of-care treatment

Ferone Diego , L. Spencer-Segal Joanna , Fidan Yaylali Guzin , Doknic Mirjana , Isaeva Elena , Dreval Alexander , Gilis-Januszewska Aleksandra , Gezer Emre , Bancos Irina , Katznelson Laurence , Harrie Maria , Svedberg Agneta , M. Pedroncelli Alberto , Tiberg Fredrik

Background: Acromegaly, a rare, chronic disorder, results from excessive growth hormone (GH) and insulin-like growth factor 1 (IGF-1). The need for convenient therapies that provide effective disease control led to the development of CAM2029, a novel, subcutaneous, octreotide depot designed for convenient monthly self-administration using pre-filled syringes/injection pens. In a 24-week Phase 3 trial (ACROINNOVA 1, NCT04076462) CAM2029 achieved superior IGF-1 control vs placeb...

2 shares

ea0099ep322 | Pituitary and Neuroendocrinology | ECE2024

An open-label long-term Phase 3 study of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly (ACROINNOVA 2): interim analysis of patient-reported outcomes

Ferone Diego , Maffei Pietro , Silverstein Julie , L. Spencer-Segal Joanna , Gilis-Januszewska Alexsandra , Doknic Mirjana , Kadioglu Pinar , Freda Pamela , Katznelson Laurence , Fidan Yaylali Guzin , Harrie Maria , Svedberg Agneta , M. Pedroncelli Alberto , Tiberg Fredrik

Background: Significant treatment-related burdens accompany standard-of-care (SoC) therapies for acromegaly, which typically require healthcare-provider administration. CAM2029 is a novel, subcutaneous octreotide depot conveniently self-administered monthly by pre-filled syringe/injection pen. In a 24-week Phase 3 trial of CAM2029 in patients with acromegaly (ACROINNOVA 1, NCT04076462), insulin-like growth factor 1 (IGF-1) response was 72.2% in patients receiving CAM2029 vs 37...

2 shares

Endocrine Abstracts

An open-label long-term Phase 3 study of CAM2029 in patients with acromegaly (ACROINNOVA 2): interim analysis of the subgroup of patients ‘new to CAM2029’ with controlled or uncontrolled acromegaly on standard-of-care treatment

An open-label long-term Phase 3 study of CAM2029, an octreotide subcutaneous depot, in patients with acromegaly (ACROINNOVA 2): interim analysis of patient-reported outcomes

BiosciAbstracts